14
Sep
Sep
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated an adequate safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the European Society for Medical Oncology (ESMO) 2024 Congress by investigators at The University of Texas MD Anderson Cancer […]